Ahmad Sheikh Zahoor, Battoo Azhar Jan, Haji Altaf Gauhar, Naveed Shah, Qurieshi Mariya Amin, Mir Abdul Wahid, Malik Tariq Rasool
Department of Surgical Oncology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, J&K 190011 India.
Department of Community Medicine, Government Medical College, Srinagar, 190002 India.
Indian J Surg Oncol. 2020 Sep;11(3):360-366. doi: 10.1007/s13193-020-01164-w. Epub 2020 Jul 12.
Recurrence is a significant problem faced in patients with esophageal cancer even after treatment with trimodal approach. We report patterns of failure in our patients of esophageal squamous cell cancer (ESCC) treated with trimodal approach. This is a single-institution retrospective analysis of 46 patients of locally advanced ESCC (treated between 2013 and 2017) managed by trimodal treatment approach. Variables were summarized using descriptive statistics. Survival statistics were estimated using Kaplan-Meier method. With a median follow-up of about 28 months, we noted an overall recurrence rate of 37% (17/46), with most of the failures being distant, with or without locoregional recurrence (4 isolated distant and 6 combined distant and locoregional). Median RFS was 34 months and median OS was yet to be reached at the last follow-up. To conclude, optimization of treatment approaches in ESCC is of utmost importance and need of the hour to further improve outcomes in these patients.
即使采用三联疗法治疗，复发仍是食管癌患者面临的一个重大问题。我们报告了接受三联疗法治疗的食管鳞状细胞癌（ESCC）患者的失败模式。这是一项单机构回顾性分析，研究对象为46例局部晚期ESCC患者（于2013年至2017年间接受治疗），采用三联治疗方法进行管理。变量使用描述性统计进行汇总。生存统计采用Kaplan-Meier方法进行估计。中位随访时间约为28个月，我们注意到总体复发率为37%（17/46），大多数失败为远处转移，伴有或不伴有局部区域复发（4例孤立远处转移和6例远处转移合并局部区域复发）。中位无复发生存期为34个月，在最后一次随访时中位总生存期尚未达到。总之，优化ESCC的治疗方法至关重要，是当前进一步改善这些患者治疗效果的迫切需求。
